

---

UNITED STATES  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of August 2025

Commission File Number: 001-41641

**SHL TELEMEDICINE LTD.**

(Translation of registrant's name into English)

**90 Yigal Alon Street**

**Tel Aviv 67891, Israel**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒

Form 40-F ☐

---

#### EXPLANATORY NOTE

On August 12, 2025, SHL Telemedicine Ltd. (the “Company”) issued a press release titled “SHL announces invitation to a Special General Meeting”. A copy of the press release is furnished herewith as Exhibit 99.1.

<u>Exhibit</u>	<u>Description</u>
<a href="#"><u>99.1</u></a>	<a href="#"><u>Press release dated August 12, 2025, issued by the Company</u></a>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**SHL TELEMEDICINE LTD.**

By: /s/ Lior Haalman  
Lior Haalman  
Chief Financial Officer

August 12, 2025

---

---



Press release

**SHL announces invitation to a Special General Meeting**

**Tel Aviv / Zurich / New York, August 12, 2025** – SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, today announced that an Special General Meeting of the Shareholders ("SGM") will be held on **September 16, 2025 at 1:00 p.m.** (Israel Time), at the Company's registered office, located at 90 Yigal Alon Street, Ashdar Building, Tel Aviv, Israel.

**The agenda shall include the following matters:**

1. Repricing of 400,000 outstanding stock options granted to Mr. David Arnon, Chief Executive Officer (CEO).
2. Grant of 100,000 stock options to the Chairman of the Board of Directors, Dr. Itamar Offer. The aforementioned grant comprises 50,000 options with an exercise price of CHF 2.75 and 50,000 options with an exercise price of CHF 3.75. The options shall vest over a period of 4 years.

The above is more fully set forth in the Notice and Proxy Statement for the SGM available on the Company's website <https://www.shl-telemedicine.com/general-meeting/>

The record date of the SGM is **August 19, 2025**.

**About SHL Telemedicine**

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957). For more information, please visit our website at [www.shl-telemedicine.com](http://www.shl-telemedicine.com).

**For further information please contact:**

Fabienne Farner, IRF, Phone : +41 43 244 81 42, [farner@irf-reputation.ch](mailto:farner@irf-reputation.ch)

---